EYA2 and breast carcinoma: We confirmed the specificity of the EGFR and EYA2 antibodies by IHC of breast cancer tissues or immunoblot with cell lysates (Supplementary Figures S7A and B) and that of miR-338-3p staining by correlation analysis of different miR-338-3p expression in breast tissues examined by hybridization and quantitative RT-PCR, respectively (Supplementary Figures S7C and D).